Genetic Variations in Individuals and Populations Flashcards
Optimizing drug therapies in the face of genetic variation
Pharmacogenetics and pharmacogenomics
The study of inherited differences (variation) in drug metabolism and response
Pharmacogenetics
Genetic variability can affect
Pharmacokinetics and pharmacodynamics
Clearance/excretion, metabolism, transportation, and absorption of drug
Pharmacokinetics
Drug activity and interaction with downstream targets
Pharmacodynamics
Pharmacogenetics encompasses
- ) Pharmacokinetics
2. ) Pharmacodynamics
A ‘genomic’ approach to pharmacogenetics –using GWAS to assess the impact of an ensemble of SNPs on the impact of drug therapy
Pharmacogenomics
Genome wide association study
GWAS
Single nucleotide polymorphism
SNPs
How do we find the international normalized ratio (INR)?
INR = PTobs / PTnormal
where,
PT = Prothrombin time
What is the normal Prothrombin Time (PT)?
11.0-13.5 seconds
56 enzymes, each encoded by a separate gene. All are heme-containing proteins expressed primarily in the liver. Responsible for detoxifying and exporting both endogenous and xenobiotic compounds
Cytochrome P450 (CYP)
CYP’s can also activate
Drugs
Accept electrons from donors such as NADPH to catalyze a number of different reactions, most importantly the addition of oxygen to C, N, or S atoms
CYPs
Phase I of drug metabolism by CYP is
Hydroxylation of molecule
Functionalization of the hydroxyl group by a sugar or acetyl group, increasing drug solubility and allowing it to be excreted
Phase II of drug metabolism by CYP
Which CYPs react with Xenobiotics?
CYP 1, 2, and 3
Six genes in particular: CYP1, CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 are responsible for the metabolism of 90% of commonly used
Drugs
Which is the most active CYP in common drug metabolism?
CYP3A4
Used in the prevention of thrombosis, embolism in cases of heart valve prosthesis, recurrent stroke, DVT, and pulmonary embolism
-2 million prescriptions per year
Warfarin (coumadin)
Impairs the synthesis of vitamin K dependent clotting factors
Warfarin (coumadin)
Warfarin inhibits a key enzyme in vitamin K recycling called
Vitamin K Epoxide Reductase
How many major sites of modification by CYPs are there on warfarin?
Five (C’s 4, 6, 7, 8, and 10)
Warfarin metabolized in the liver cell by C7 hydroxylation or C6 hydroxylation by CYP2C9
S-Warfarin
There is significant variation in the individual activity levels of
Cytochrome P450s
Is the CYP2C9 interaction with warfarin considered a component of Pharmacokinetics or Pharmacodynamics?
Pharmacokinetics
The action of drugs in the body over a period of time, including the processes of absorption, distribution, and localization in tissues
Pharmacokinetics
Classified as poor, normal, or ultrafast metabolizers
CYP variants
Which CYP2C9 variant has a 25% dose reduction?
CYP2C9*2
Which CYP2C9 variant has a 35% dose reduction?
CYP2C9*3
What is the recommended target therapeutic range for INR?
INR = 2.0 - 3.0
CYP variants are classified as
Poor (PM), Normal (intermediate, IM), or Ultrafast (extensive, EM) metabolizers
In the CYP2C9 family, what is an extensive metabolizer?
Wild type: CYP2C911
In the CYP2C9 family, what are intermediate metabolizers?
12 and 13 variants
In the CYP2C9 family, what are poor metabolizers?
22, 23, and 33 variants
Vitamin K epoxide reductase (gene: VKORC1) is a target of
Warfarin
Inhibition of VKORC1 by warfarin prevents regeneration of reduced vitamin K, which is necessary for gamma glutamyl carboxylation of
Coagulation factors
Prevents regeneration of reduced vitamin K, which is necessary for gamma glutamyl carboxylation of coagulation factors
Inhibition of VKORC1 by warfarin
Single nucleotide polymorphisms (SNPs) in VKORC1 correlate with
Warfarin sensitivity
Is the VKORC1 interaction with warfarin considered a component of pharmacokinetics or pharmacodynamics?
Pharmacodynamics
Deals with drug activity and interaction with downstream targets
Pharmacodynamics
Combinations of alleles or genetic markers which occur more or less frequently than expected at random
Linkage Disequilibrium
Account for approximately 30% of variation in Warfarin sensitivity
VKORC1 + CYP2C9
Accounts for another 1-2% of warfarin sensitivity (according to a GWAS study of 2000 patients)
CYP4F2
SNPs in CYP2C18 and CYP2C19 also correlate with a
Warfarin sensitivity
Codeine intoxication is associated with ultra-rapid
CYP2D6 metabolism
A study found that there are 3+ copies of the CYP2D6 allele, which indicates
Gene duplication
It was then found that naturally occurring variation in CYP3A4 has no observable effect on
Optimal codeine dosage
The combination of the gene duplication in CYP2D6 and the natural variation in CYP3A4 resulted in ultra-rapid conversion of codeine to
Morphine
- 10%converted by CYP2D6
- 80% cleared by CYP3A4
Have provided valuable data in the areas of pharmacogenetics and pharmacogenomics. This is especially the case for adverse drug reactions attributable to alleles of a single gene, often one that encodes an enzyme contributing to metabolism of the
drug.
Candidate-gene studies
What are some of the factors that have limited GWA studies to date?
Sample size, phenotypic characterization, replication of findings, and effect size
Encodes the main metabolizing enzyme for coumarin anticoagulants such as Warfarin
CYP2C9 gene
Markers in which two genes are the main predictors for coumarin dosage?
VKORC1 and CYP2C9 genes
Accounts for approximately 1.5% of warfarin dosage variability
CYP4F2 SNP
When a higher dose is required for therapeutic affect
Tolerance
When a lower dose is required for therapeutic affect
Intolerance/sensitivity
Has nothing to do with the mechanism of action of the drug.
-Just tells us how well the drug gets to its target
Pharmacokinetics (PK)
Tells us about the drugs activity and how well it interacts with its downstream targets
Pharmacodynamics
Tells us how quickly our blood clots
Prothrombin time (PT)
The therapeutic window is an INR of 2-3, below the therapeutic window, the drug is not helpful. Above the therapeutic window, the drug is
Toxic
CYPs are mostly expressed in the
Liver
CYPs can activate drugs, an example of this is the activation of codeine to morphine by
CYP2D6
The conversion of acetometophin to N-Acetyl-P-Benzoquinone imine by CYP3A4 is an example of how CYPs can be
Harmful
We are given a racemic mixture of Warfarin, but which isomer is more active?
S-warfarin
Processed by CYP2C9 into 7-hydroxywarfarin or 6-hydroxywarfarin
S-Warfarin
Multi-drug transporters that will push all xenobiotics out of the cell
ABC transporters
An example of pharmacokinetics because it deals with how the drug is distributed and how it is processed
CYP2C9 interaction with Warfarin
The safe therapeutiv window represents
Pharmacodynamic effects
An Arg–>Cys mutation that results in reduced affinity for P450 reductase, which makes you more sensitive to Warfarin
-requires 25% lower dosage
CYP2C9*2
An Ile–>Leu mutation that alters substrate specificity of CYP2C9 and will make you more sensitive to Warfarin
-requires 35% lower dosage
CYP2C9*3
Gamma glutamyl carboxylation is necessary for
Coagulation